Table 2

Occurrence of AU before and during treatment

TreatmentAU-diagnosis prior to treatment startPatients with ≥1 AU-diagnosis during treatmentFollow-up days, mean
Within 10 yearsWithin 1 yearAllNew onset*New onset* biologics-naïve†
Main cohort: excluding patients with an AU-diagnosis in year prior to treatment start
Secukinumab n=456, n (%)52 (11)013 (2.9)5 (1.3)1 (3.3)367
Adalimumab n=1006, n (%)154 (15)025 (2.5)4 (0.5)2 (0.5)485
Infliximab n=783, n (%)80 (10013 (1.7)4 (0.6)2 (0.4)473
Etanercept n=1800, n (%)171 (10)052 (2.9)19 (1.2)9 (0.8)454
Golimumab n=500, n (%)73 (15)022 (4.4)5 (1.2)4 (1.9)689
Certolizumab n=306, n (%)44 (14)06 (2.0)4 (1.6)0425
Overall cohort: all patients starting secukinumab or a TNFi in 2015–2018
Secukinumab n=493, n (%)89 (18)37 (8)31 (6)5 (1.3)1 (3.3)380
Adalimumab n=1249, n (%)397 (32)243 (19)143 (11)4 (0.5)2 (0.5)490
Infliximab n=883, n (%)180 (20)100 (11)54 (6)4 (0.6)2 (0.4)473
Etanercept n=1898, n (%)269 (14)98 (5)104 (5)19 (1.2)9 (0.8)459
Golimumab n=562, n (%)135 (24)62 (11)56 (10)5 (1.2)4 (1.9)694
Certolizumab n=335, n (%)73 (22)29 (9)25 (7)4 (1.6)0420
  • *New-onset AU=AU-diagnosis registered during treatment in patients with no AU-diagnosis prior to treatment start (the denominator is the number of patients starting the respective treatment having no prior registration of AU since start of outpatient register in 2001).

  • †Previously biologics-naïve patients.

  • AU, anterior uveitis; TNFi, tumour necrosis factor inhibitors.